通过局限性与全身性疾病形式的分子谱分析对滤泡性淋巴瘤发病机制的新见解
该研究对147例局限性滤泡性淋巴瘤(lFL)和122例全身性滤泡性淋巴瘤(sFL)进行体细胞拷贝数改变(SCNA)和全外显子测序(WES)分析,发现lFL与sFL在SCNA和突变谱上总体重叠,但18q增益频率在lFL为14%、sFL为36%(p=0.0003),且lFL中18q21增益与更差的无进展生存期(PFS)相关;ARID1A突变在sFL为29%、lFL为6%(p=0.0001)。
要点
- lFL与sFL在SCNA和突变谱上总体重叠,但18q增益频率lFL 14% vs sFL 36%(p=0.0003)。
- lFL中18q21增益虽罕见,但与更差的无进展生存期(PFS)相关。
- ARID1A突变在sFL 29% vs lFL 6%(p=0.0001),BCL2+与BCL2- FL突变谱存在差异。
核心结论
- lFL与sFL的SCNA和突变谱总体重叠,但分子谱分析揭示新见解并确定18q21增益为lFL的预后标志物。
研究设计与样本
- 对147例lFL和122例sFL进行体细胞拷贝数改变(SCNA)谱分析和全外显子测序(WES),并对候选靶标进行基因和蛋白表达分析。
主要发现
- lFL与sFL之间SCNA频率存在显著差异,如18q增益在lFL为14%、sFL为36%(p=0.0003)。
- lFL中18q21增益虽罕见,但与更差的无进展生存期(PFS)相关。
- ARID1A突变在sFL为29%、lFL为6%(p=0.0001)。
- BCL2+ FL中KMT2D、BCL2、ABL2、IGLL5和ARID1A突变富集,而STAT6突变更常见于BCL2- FL。
关键数值与推荐
- 18q增益频率:lFL 14% vs sFL 36%(p=0.0003)。
- ARID1A突变频率:sFL 29% vs lFL 6%(p=0.0001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Knowledge on the pathogenesis of FL is mainly based on data derived from advanced/systemic stages of FL (sFL) and only small cohorts of localized FL (lFL) have been characterized intensively so far. Comprehensive analysis with profiling of somatic copy number alterations (SCNA) and whole exome sequencing (WES) was performed in 147 lFL and 122 sFL. Putative targets were analyzed for gene and protein expression. Overall, lFL and sFL, as well as BCL2 translocation-positive (BCL2+) and -negative (BCL2-) FL showed overlapping features in SCNA and mutational profiles. Significant differences between lFL and sFL, however, were detected for SCNA frequencies, e.g., in 18q-gains (14% lFL vs. 36% sFL; p = 0.0003). Although rare in lFL, gains in 18q21 were associated with inferior progression-free survival (PFS). The mutational landscape of lFL and sFL included typical genetic lesions. However, ARID1A mutations were significantly more often detected in sFL (29%) compared to lFL (6%, p = 0.0001). In BCL2 + FL mutations in KMT2D, BCL2, ABL2, IGLL5 and ARID1A were enriched, while STAT6 mutations more frequently occurred in BCL2- FL. Although the landscape of lFL and sFL showed overlapping features, molecular profiling revealed novel insights and identified gains in 18q21 as prognostic marker in lFL.
引用
- Kalmbach S, Grau M, Zapukhlyak M, et al. Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms. Leukemia. 2023. PMID: 37563306. doi:10.1038/s41375-023-01995-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。